At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
KN026 combinationdrug
Likely dose
KN026 combination 30 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With KN046 in Patients With Locally Advanced Unresectable or Metastatic HER2-positive Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd·interventional·Posted Aug 20, 2020·Updated Sep 21, 2023
In Brief
A Phase 2 clinical trial evaluating KN026 combination for HER2-positive Solid Tumors. Completed, enrolled 102 participants across 1 site.
Detailed Summary
This is an open-label, phase II，multi-center study to evaluate the efficacy, safety and tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2-positive Solid Tumors
CountriesChina
CollaboratorsPeking University
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartDec 2020
Primary CompletionJan 2022
Study CompletionMay 2023
TodayJul 2026
First PostedAug 20, 2020
Enrollment StartDec 7, 2020
Primary CompletionJan 12, 2022
Study CompletionMay 22, 2023
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 5.9 years ago
Interventions
KN026 combinationdrug
30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046